Chris joined Oxford Science Enterprises in December 2019 and advises the Life Sciences team.
He is a seasoned biotech entrepreneur with over 35 years’ experience in the biotechnology industry.
Chris has considerable experience of leading and growing early-stage companies and the transition to mid-stage clinical development organisations. He also has extensive international transactional experience across both listed and private companies including fundraising, licensing and M&A activities.
Chris was formerly a Partner at Syncona, a FTSE250 company, where he was also founding CEO of Achilles Therapeutics (NASDAQ: ACHL). Prior to this he was CEO of Argenta Discovery, which was sold to Galapagos NV (Euronext and NASDAQ: GLPG), and Pulmagen Therapeutics.
Chris holds a PhD from the University of Manchester and carried out post-doctoral research at the Massachusetts Institute of Technology.
